[Problem of drug-resistant tuberculosis and the way of its solution].
Drug-resistant tuberculosis in the Ukraine and in other countries as well is a great important problem. The presence of drug-resistant Mycobacteria worsens clinical and bacteriological responses to therapy, prolongs hospital stay, and increases costs. The novel derivative of rifampicin, rifabutin, produced by Pharmacia & Upjohn under the trade name Mycobutin is more effective and safe than rifampicin. Rifabutin is approved for clinical application for tuberculosis and other mycobacterial infections. It is also recommended for rifampicin-resistant tuberculosis.
Pukhlik
B M
BM
D000904:Antibiotics, Antitubercular / Q000493:pharmacokinetics / Q000627:therapeutic use*; D014943:Global Health; D006801:Humans; D015994:Incidence; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D017828:Rifabutin / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016896:Treatment Outcome; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy / Q000453:epidemiology / Q000378:metabolism
D000904:Antibiotics, Antitubercular; D017828:Rifabutin